Skip to content

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Lung Cancer

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria

* Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
* Participants must have a life expectancy of at least 3 months at the time of the first dose.

Exclusion Criteria

* Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
* Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
* Participants must not have a history of serious recurrent infections.
* Participants must not have a history of severe heart disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study Location

Local Institution - 0025
Local Institution - 0025
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Site 0025

Local Institution - 0026
Local Institution - 0026
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Site 0026

Local Institution - 0024
Local Institution - 0024
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Site 0024

Local Institution - 0022
Local Institution - 0022
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Site 0022

Local Institution - 0023
Local Institution - 0023
Ottawa, Ontario
Canada

Contact Study Team

Centre Hospitalier de l'Université de Montréal
Centre Hospitalier de l'Université de Montréal
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Marie Florescu, Site 0022

5148908000
Jewish General Hospital
Jewish General Hospital
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Jennifer Friedmann, Site 0025

514340822224915
Study Sponsored By
Bristol-Myers Squibb
Participants Required
More Information
Study ID: NCT06618287